| Dr Illiana Alexandrova Morgan, MD | |
|
1945 Highway 33, Neptune, NJ 07753 | |
| (248) 763-9157 | |
| Not Available |
| Full Name | Dr Illiana Alexandrova Morgan |
|---|---|
| Gender | Female |
| Speciality | Anesthesiology |
| Experience | 17 Years |
| Location | 1945 Highway 33, Neptune, New Jersey |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083992416 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 25MA09060900 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Jersey Shore University Medical Center | Neptune, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Jersey Shore Anesthesiology Associates Pa | 9830003052 | 76 |
News Archive
PharmaNet Development Group, Inc., a leading provider of clinical development services to innovative pharmaceutical, biotechnology, generic drug and medical device companies, today announced that the United States Securities and Exchange Commission (SEC) has notified the Company that it has completed a two and half year investigation of the Company related to revenue recognition, earnings, company operations and related party transactions and does not intend to recommend any enforcement action by the Commission. The investigation, which is now closed, was originally initiated as an informal investigation in 2006 and became formal in March 2007.
Johns Hopkins researchers report that once a growing nerve "tastes" a certain protein, it loses its "appetite" for other proteins and follows the tasty crumbs to reach its final destination.
Blame it on your genes? Researchers from The Miriam Hospital's Weight Control and Diabetes Research Center say individuals with variations in certain "obesity genes" tend to eat more meals and snacks, consume more calories per day and often choose the same types of high fat, sugary foods.
Despite their changed body size, pregnant women are just as good as other people at judging whether they are able to fit through openings, such as doorways, or not.
Isis Pharmaceuticals, Inc. announced today that it has initiated Phase 1 clinical studies for ISIS-GCGRRx and ISIS-GCCRRx, antisense drugs Isis is developing for the treatment of type 2 diabetes.
› Verified 7 days ago
| Entity Name | Jersey Shore Anesthesiology Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538190764 PECOS PAC ID: 9830003052 Enrollment ID: O20031113000003 |
News Archive
PharmaNet Development Group, Inc., a leading provider of clinical development services to innovative pharmaceutical, biotechnology, generic drug and medical device companies, today announced that the United States Securities and Exchange Commission (SEC) has notified the Company that it has completed a two and half year investigation of the Company related to revenue recognition, earnings, company operations and related party transactions and does not intend to recommend any enforcement action by the Commission. The investigation, which is now closed, was originally initiated as an informal investigation in 2006 and became formal in March 2007.
Johns Hopkins researchers report that once a growing nerve "tastes" a certain protein, it loses its "appetite" for other proteins and follows the tasty crumbs to reach its final destination.
Blame it on your genes? Researchers from The Miriam Hospital's Weight Control and Diabetes Research Center say individuals with variations in certain "obesity genes" tend to eat more meals and snacks, consume more calories per day and often choose the same types of high fat, sugary foods.
Despite their changed body size, pregnant women are just as good as other people at judging whether they are able to fit through openings, such as doorways, or not.
Isis Pharmaceuticals, Inc. announced today that it has initiated Phase 1 clinical studies for ISIS-GCGRRx and ISIS-GCCRRx, antisense drugs Isis is developing for the treatment of type 2 diabetes.
› Verified 7 days ago
| Entity Name | Specialty Anesthesia Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932290111 PECOS PAC ID: 3577512789 Enrollment ID: O20050114000208 |
News Archive
PharmaNet Development Group, Inc., a leading provider of clinical development services to innovative pharmaceutical, biotechnology, generic drug and medical device companies, today announced that the United States Securities and Exchange Commission (SEC) has notified the Company that it has completed a two and half year investigation of the Company related to revenue recognition, earnings, company operations and related party transactions and does not intend to recommend any enforcement action by the Commission. The investigation, which is now closed, was originally initiated as an informal investigation in 2006 and became formal in March 2007.
Johns Hopkins researchers report that once a growing nerve "tastes" a certain protein, it loses its "appetite" for other proteins and follows the tasty crumbs to reach its final destination.
Blame it on your genes? Researchers from The Miriam Hospital's Weight Control and Diabetes Research Center say individuals with variations in certain "obesity genes" tend to eat more meals and snacks, consume more calories per day and often choose the same types of high fat, sugary foods.
Despite their changed body size, pregnant women are just as good as other people at judging whether they are able to fit through openings, such as doorways, or not.
Isis Pharmaceuticals, Inc. announced today that it has initiated Phase 1 clinical studies for ISIS-GCGRRx and ISIS-GCCRRx, antisense drugs Isis is developing for the treatment of type 2 diabetes.
› Verified 7 days ago
| Entity Name | North American Partners In Anesthesia Of New Jersey Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548433048 PECOS PAC ID: 5890867410 Enrollment ID: O20080626000318 |
News Archive
PharmaNet Development Group, Inc., a leading provider of clinical development services to innovative pharmaceutical, biotechnology, generic drug and medical device companies, today announced that the United States Securities and Exchange Commission (SEC) has notified the Company that it has completed a two and half year investigation of the Company related to revenue recognition, earnings, company operations and related party transactions and does not intend to recommend any enforcement action by the Commission. The investigation, which is now closed, was originally initiated as an informal investigation in 2006 and became formal in March 2007.
Johns Hopkins researchers report that once a growing nerve "tastes" a certain protein, it loses its "appetite" for other proteins and follows the tasty crumbs to reach its final destination.
Blame it on your genes? Researchers from The Miriam Hospital's Weight Control and Diabetes Research Center say individuals with variations in certain "obesity genes" tend to eat more meals and snacks, consume more calories per day and often choose the same types of high fat, sugary foods.
Despite their changed body size, pregnant women are just as good as other people at judging whether they are able to fit through openings, such as doorways, or not.
Isis Pharmaceuticals, Inc. announced today that it has initiated Phase 1 clinical studies for ISIS-GCGRRx and ISIS-GCCRRx, antisense drugs Isis is developing for the treatment of type 2 diabetes.
› Verified 7 days ago
| Entity Name | Allied Digestive Health Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265831259 PECOS PAC ID: 5991027583 Enrollment ID: O20141210001569 |
News Archive
PharmaNet Development Group, Inc., a leading provider of clinical development services to innovative pharmaceutical, biotechnology, generic drug and medical device companies, today announced that the United States Securities and Exchange Commission (SEC) has notified the Company that it has completed a two and half year investigation of the Company related to revenue recognition, earnings, company operations and related party transactions and does not intend to recommend any enforcement action by the Commission. The investigation, which is now closed, was originally initiated as an informal investigation in 2006 and became formal in March 2007.
Johns Hopkins researchers report that once a growing nerve "tastes" a certain protein, it loses its "appetite" for other proteins and follows the tasty crumbs to reach its final destination.
Blame it on your genes? Researchers from The Miriam Hospital's Weight Control and Diabetes Research Center say individuals with variations in certain "obesity genes" tend to eat more meals and snacks, consume more calories per day and often choose the same types of high fat, sugary foods.
Despite their changed body size, pregnant women are just as good as other people at judging whether they are able to fit through openings, such as doorways, or not.
Isis Pharmaceuticals, Inc. announced today that it has initiated Phase 1 clinical studies for ISIS-GCGRRx and ISIS-GCCRRx, antisense drugs Isis is developing for the treatment of type 2 diabetes.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Illiana Alexandrova Morgan, MD 351 Cedarcroft Dr, Brick, NJ 08724-4401 Ph: (248) 763-9157 | Dr Illiana Alexandrova Morgan, MD 1945 Highway 33, Neptune, NJ 07753 Ph: (248) 763-9157 |
News Archive
PharmaNet Development Group, Inc., a leading provider of clinical development services to innovative pharmaceutical, biotechnology, generic drug and medical device companies, today announced that the United States Securities and Exchange Commission (SEC) has notified the Company that it has completed a two and half year investigation of the Company related to revenue recognition, earnings, company operations and related party transactions and does not intend to recommend any enforcement action by the Commission. The investigation, which is now closed, was originally initiated as an informal investigation in 2006 and became formal in March 2007.
Johns Hopkins researchers report that once a growing nerve "tastes" a certain protein, it loses its "appetite" for other proteins and follows the tasty crumbs to reach its final destination.
Blame it on your genes? Researchers from The Miriam Hospital's Weight Control and Diabetes Research Center say individuals with variations in certain "obesity genes" tend to eat more meals and snacks, consume more calories per day and often choose the same types of high fat, sugary foods.
Despite their changed body size, pregnant women are just as good as other people at judging whether they are able to fit through openings, such as doorways, or not.
Isis Pharmaceuticals, Inc. announced today that it has initiated Phase 1 clinical studies for ISIS-GCGRRx and ISIS-GCCRRx, antisense drugs Isis is developing for the treatment of type 2 diabetes.
› Verified 7 days ago
Marie E Maroulakos, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1945 Highway 33, Neptune, NJ 07753 Phone: 732-897-0200 Fax: 732-897-0263 | |
William J Rahal, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1945 State Route 33, Neptune, NJ 07753 Phone: 732-897-0200 Fax: 732-897-0263 | |
Dean P Cindrario, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1945 State Route 33, Neptune, NJ 07753 Phone: 732-897-0200 Fax: 732-897-0263 | |
Vincent N Cirella, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1945 Highway 33, Neptune, NJ 07753 Phone: 732-897-0200 Fax: 732-897-0263 | |
Khaled M Morsi, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1945 State Route 33, Neptune, NJ 07753 Phone: 732-897-0200 | |
Farys R Chowdhury, DO Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1945 State Route 33, Neptune, NJ 07753 Phone: 732-775-5500 |